Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Improvement of residual dizziness associated with a low-dose vitamin D-calcium combination (Caltrate D) supplementation in female patients with benign paroxysmal positional vertigo after successful repositioning: an 8-week retrospective study
Study design awaiting verification · Frontiers in Nutrition · 2026
Original publication title
Improvement of residual dizziness associated with a low-dose vitamin D-calcium combination (Caltrate D) supplementation in female patients with benign paroxysmal positional vertigo after successful repositioning: an 8-week retrospective study
Copyright © 2026 Han, Li, Fan, Guan, Liu, Fan and Wu.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Residual dizziness (RD) is a common and debilitating symptom following successful canalith repositioning procedure (CRP) for benign paroxysmal positional vertigo (BPPV). Currently, no effective pharmacological treatment exists for this condition. Our previous work identified low serum 25-hydroxyvitamin D [25(OH)D] as an independent risk factor for RD. This study therefore evaluated whether 8-week supplementation with Caltrate D was associated with improvement in RD.
Source: BackgroundAbstract: What methods does the paper describe?
Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD.
Source: MethodsAbstract: Results
Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7 to 18 vs. 19 days, IQR 12 to 24; p = 0.007) than in the control group.
Source: ResultsAbstract: Conclusion
In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.
Source: ConclusionAuthors’ abstract
Background
Residual dizziness (RD) is a common and debilitating symptom following successful canalith repositioning procedure (CRP) for benign paroxysmal positional vertigo (BPPV). Currently, no effective pharmacological treatment exists for this condition. Our previous work identified low serum 25-hydroxyvitamin D [25(OH)D] as an independent risk factor for RD. This study therefore evaluated whether 8-week supplementation with Caltrate D was associated with improvement in RD.
Methods
Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD.
Results
Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7 to 18 vs. 19 days, IQR 12 to 24; p = 0.007) than in the control group.
Conclusion
In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.
Publication and source details
Original title: Improvement of residual dizziness associated with a low-dose vitamin D-calcium combination (Caltrate D) supplementation in female patients with benign paroxysmal positional vertigo after successful repositioning: an 8-week retrospective study
Weiwei Han; Ange Li; Zhenyi Fan; Qiongfeng Guan; Xiaoxia Liu; Weinv Fan; Yunqin Wu
Frontiers in Nutrition · 2026
* Correspondence: Yunqin Wu, wu_yunqin@126.comCopyright © 2026 Han, Li, Fan, Guan, Liu, Fan and Wu.2026Han, Li, Fan, Guan, Liu, Fan and Wuhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Medical Scientific Research Foundation of Zhejiang Province, China (Grant Nos. 2023KY1085 and 2024KY1553), the Hwa Mei Foundation (No. 2023HMKY45), and AI-Enabled Design Synthesis Biological Evaluation, and Clinical Development of Innovative Therapeutics for Ischemic Stroke (Grant No. SIML-202306).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-08T08:19:33+00:00
DOI: 10.3389/fnut.2026.1928365 · PMC13630625